Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03506477 · ClinicalTrials.gov registry record · Phase 4
Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT03506477 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 25 participants.
The verdict
NCT03506477, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques in skin of color (and its change with Enstilar ® treatment) as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life.
Interventions
- DRUG Vehicle foam
- DRUG Enstilar® foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2019-09-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03506477
The ClinicalTrials.gov registry entry for NCT03506477 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle foam is the first listed.
NCT03506477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03506477 about?
NCT03506477 is a clinical study titled "Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color". This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST IV-VI). This study will a...
What is the current status of trial NCT03506477?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2018-05-21. Estimated completion is 2019-09-25.
What interventions are being tested in trial NCT03506477?
The interventions under investigation include: Vehicle foam (DRUG), Enstilar® foam (DRUG).
Who is sponsoring clinical trial NCT03506477?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.